← Back to Search

Continuous Glucose Monitoring for Metabolic Health

N/A

Recruiting

Research Sponsored by Signos Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years and above

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up during enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.

Awards & highlights

Study Summary

This trial looks at how CGM and mHealth platforms can help people with obesity, pre-diabetes, and diabetes make changes to diet and exercise to improve health.

Who is the study for?

This trial is for adults who can read English, own a smartphone to use the Signos App, and are willing to input data and complete surveys. It's not for those with Type 1 or Type 2 Diabetes, history of bariatric surgery, severe diseases that limit diet/exercise, certain medication users, or those with eating disorders.Check my eligibility

What is being tested?

The study tests if using a Continuous Glucose Monitor (CGM) device helps non-diabetic people lose weight when combined with the Signos mobile health platform through coaching and nutrition education.See study design

What are the potential side effects?

Potential side effects may include skin irritation from the CGM device adhesive. However, since this is a non-invasive monitoring tool in a generally healthy population, significant side effects are not commonly expected.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ during enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~during enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and during enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Average fasting glucose

Change in weight

Secondary outcome measures

Body composition

Time in range

Trial Design

1Treatment groups

Experimental Treatment

Group I: Signos digital health app and CGMExperimental Treatment1 Intervention

For all consented participants, the Signos app will use CGM data to provide recommendations customized to users for promoting general health and wellness.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Signos IncLead Sponsor

2 Previous Clinical Trials

20,380 Total Patients Enrolled

Media Library

Signos digital health app and CGM Clinical Trial Eligibility Overview. Trial Name: NCT05121844 — N/A

Abdominal Obesity Research Study Groups: Signos digital health app and CGM

Abdominal Obesity Clinical Trial 2023: Signos digital health app and CGM Highlights & Side Effects. Trial Name: NCT05121844 — N/A

Signos digital health app and CGM 2023 Treatment Timeline for Medical Study. Trial Name: NCT05121844 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies in this clinical research project for participants?

"Affirmative. Information hosted on clinicaltrials.gov reveals that this investigation, first published on November 2nd 2021, is currently selecting participants. Approximately 50000 individuals must be recruited from two separate medical centres for the study to successfully progress."

Answered by AI

How many participants are currently being enrolled in this trial?

"Affirmative. Data accessible on clinicaltrials.gov indicates that this experiment has been actively looking for participants since November 2nd 2021 and was last updated on May 16th 2023. This trial is aiming to recruit 50000 patients from two different sites."

Answered by AI